Cargando…

Pattern of drug resistance of Mycobacterium tuberculosis clinical isolates to first-line antituberculosis drugs in pulmonary cases

CONTEXT: Mycobacterium tuberculosis (MTB), the human pathogen causes Tuberculosis (TB). It is a highly infectious and globally pandemic disease. The severity increases when the MTB becomes resistant to antituberculosis drugs. India is reported to be in the second place, with the highest number of dr...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalo, Deepika, Kant, Surya, Srivastava, Kanchan, Sharma, Ajay K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4502197/
https://www.ncbi.nlm.nih.gov/pubmed/26180382
http://dx.doi.org/10.4103/0970-2113.159561
_version_ 1782381161081733120
author Kalo, Deepika
Kant, Surya
Srivastava, Kanchan
Sharma, Ajay K.
author_facet Kalo, Deepika
Kant, Surya
Srivastava, Kanchan
Sharma, Ajay K.
author_sort Kalo, Deepika
collection PubMed
description CONTEXT: Mycobacterium tuberculosis (MTB), the human pathogen causes Tuberculosis (TB). It is a highly infectious and globally pandemic disease. The severity increases when the MTB becomes resistant to antituberculosis drugs. India is reported to be in the second place, with the highest number of drug-resistant TB cases. The treatment of drug-resistant TB is even more complicated. MATERIALS AND METHODS: The present study comprises of 159 TB patients, in which 88 are reported to have drug-resistant TB (55.3%). All the patients are in the age group of 18–70 years. Patients having extrapulmonary TB and diabetes were excluded from the study. The collected samples were processed and stained for acid fastness and smear positivity. They were subjected to inoculation on Lowenstein–Jensen (LJ) slants. RESULTS: The results showed that out of the four drugs — Streptomycin, Isoniazid, Rifampicin, and Ethambutol — the resistant cases reported in Streptomycin were 45 (24.9%), whereas, in Isoniazid, Rifampicin, and Ethambutol, the resistant cases were 62 (34.2%), 27 (14.9%), and 47 (26.0%), respectively. Isoniazid showed the highest percentage of resistance among the patients. CONCLUSION: Effective measures such as convincing the patients to take the prescribed drugs and follow the five major strategies under the Directly Observed Treatment, Short Course (DOTS), could help in managing such cases.
format Online
Article
Text
id pubmed-4502197
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-45021972015-07-15 Pattern of drug resistance of Mycobacterium tuberculosis clinical isolates to first-line antituberculosis drugs in pulmonary cases Kalo, Deepika Kant, Surya Srivastava, Kanchan Sharma, Ajay K. Lung India Original Article CONTEXT: Mycobacterium tuberculosis (MTB), the human pathogen causes Tuberculosis (TB). It is a highly infectious and globally pandemic disease. The severity increases when the MTB becomes resistant to antituberculosis drugs. India is reported to be in the second place, with the highest number of drug-resistant TB cases. The treatment of drug-resistant TB is even more complicated. MATERIALS AND METHODS: The present study comprises of 159 TB patients, in which 88 are reported to have drug-resistant TB (55.3%). All the patients are in the age group of 18–70 years. Patients having extrapulmonary TB and diabetes were excluded from the study. The collected samples were processed and stained for acid fastness and smear positivity. They were subjected to inoculation on Lowenstein–Jensen (LJ) slants. RESULTS: The results showed that out of the four drugs — Streptomycin, Isoniazid, Rifampicin, and Ethambutol — the resistant cases reported in Streptomycin were 45 (24.9%), whereas, in Isoniazid, Rifampicin, and Ethambutol, the resistant cases were 62 (34.2%), 27 (14.9%), and 47 (26.0%), respectively. Isoniazid showed the highest percentage of resistance among the patients. CONCLUSION: Effective measures such as convincing the patients to take the prescribed drugs and follow the five major strategies under the Directly Observed Treatment, Short Course (DOTS), could help in managing such cases. Medknow Publications & Media Pvt Ltd 2015 /pmc/articles/PMC4502197/ /pubmed/26180382 http://dx.doi.org/10.4103/0970-2113.159561 Text en Copyright: © Lung India http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kalo, Deepika
Kant, Surya
Srivastava, Kanchan
Sharma, Ajay K.
Pattern of drug resistance of Mycobacterium tuberculosis clinical isolates to first-line antituberculosis drugs in pulmonary cases
title Pattern of drug resistance of Mycobacterium tuberculosis clinical isolates to first-line antituberculosis drugs in pulmonary cases
title_full Pattern of drug resistance of Mycobacterium tuberculosis clinical isolates to first-line antituberculosis drugs in pulmonary cases
title_fullStr Pattern of drug resistance of Mycobacterium tuberculosis clinical isolates to first-line antituberculosis drugs in pulmonary cases
title_full_unstemmed Pattern of drug resistance of Mycobacterium tuberculosis clinical isolates to first-line antituberculosis drugs in pulmonary cases
title_short Pattern of drug resistance of Mycobacterium tuberculosis clinical isolates to first-line antituberculosis drugs in pulmonary cases
title_sort pattern of drug resistance of mycobacterium tuberculosis clinical isolates to first-line antituberculosis drugs in pulmonary cases
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4502197/
https://www.ncbi.nlm.nih.gov/pubmed/26180382
http://dx.doi.org/10.4103/0970-2113.159561
work_keys_str_mv AT kalodeepika patternofdrugresistanceofmycobacteriumtuberculosisclinicalisolatestofirstlineantituberculosisdrugsinpulmonarycases
AT kantsurya patternofdrugresistanceofmycobacteriumtuberculosisclinicalisolatestofirstlineantituberculosisdrugsinpulmonarycases
AT srivastavakanchan patternofdrugresistanceofmycobacteriumtuberculosisclinicalisolatestofirstlineantituberculosisdrugsinpulmonarycases
AT sharmaajayk patternofdrugresistanceofmycobacteriumtuberculosisclinicalisolatestofirstlineantituberculosisdrugsinpulmonarycases